|
Published by: NeuroInsights, LLC
Published: Aug. 1, 2012 - 583 Pages
Table of Contents- 1: Executive Summary
- The Brain Industry Revealed
- Neuropharmaceuticals
- Cell Therapies
- Neurodevices
- Neurodiagnostics
- Investment Risks and Opportunities
- Translating Neuroscience into Neurotech
- The Neurotech Market Opportunity
- Key Industry Facts and Findings
- 2: Trends and Drivers
- Converging Technology Drivers
- Crossing the Blood Brain Barrier
- Demographic Drivers
- More People Living Longer
- Social Drivers
- The Lifestyle Improvement Market
- Economic Drivers
- Global Economic Burden of Brain-Related Illness
- Rising Health Care Costs
- Research Funding
- US Government Research Funding
- Stem Cell Funding
- International Government Research Funding
- Foundations Focus on the Brain
- Intellectual Property Trends
- Global Intellectual Property Protection
- Patent Expirations
- Neurotech Merger and Acquisition Activity (2005-Q12012)
- 3: Neuropharmaceutical Sector
- Neuropharmaceutical Sector Overview
- Trends in Neuropharmaceuticals
- Big Pharma Scales Back
- Treatments in Development and Abandoned by Indication 2006-2012
- Neuropharmaceutical Partnering and Licensing
- Partnering and Licensing Personnel
- Partnering and Licensing Deals 2004-Q12012
- Neurology Markets and Pipelines
- Alzheimer’s Disease (AD)
- AAMI and MCI
- Epilepsy and Seizure Disorders
- Huntington's disease
- Migraine
- Multiple Sclerosis
- Parkinson’s Disease
- Sleep Disorders
- Restless Legs Syndrome
- Stroke
- Traumatic Brain Injury
- Psychiatry Markets and Pipelines
- Addiction
- Anxiety Disorders
- Attention Disorders
- Depressive Disorders
- Bipolar Disorder
- Obesity
- Schizophrenia
- Cognitive Impairment Associated with Schizophrenia
- Sensory Markets and Pipelines
- Pain
- Retinal Disorders
- 4: Stem Cells and Neuroregeneration
- Defining Stem Cell Markets and Players
- Therapeutics
- Drug Discovery Tools
- Stem Cell Banking
- Stem Cell Approaches
- Background
- The Science of Transplantion
- Controlling Immune Rejection and Infection
- Sources and Harvesting of Stem Cells
- Embronic Stem Cells
- Fetal Stem Cells
- Adult Stem Cells
- Stimulation of Endogenous Stem Cells
- Stem Cells Scientific Hurdles
- Markets and Treatments in Development
- Alzheimer’s Disease
- Amyotrophic Lateral Sclerosis (ALS)
- Hearing Loss
- Huntington’s Disease (HD)
- Multiple Sclerosis (MS)
- Parkinson’s Disease
- Retinal Disorders
- Spinal Cord Injury (SCI)
- Stroke
- Other CNS Diseases
- 5: Neurodevice Sector
- Neurodevice Sector Overview
- Neurodevice Markets
- Regulatory Process in the US
- Regulatory Process in the EU
- Neurodevice Sector Trends
- Investment by Major Device companies
- Neurodevice M&A Activity (2005-Q12012)
- Neuroprosthetic Devices
- Cochlear Implants
- Retinal Implants
- Motor Prostheses and Brain Computer Interfaces
- Neuromodulation Devices
- Neuromodulation Device Clinial Trials and Recent Approvals
- Deep Brain Stimulation
- Essential Tremor
- Parkinson’s Disease
- Primary Dystonia
- Severe Obsessive Compulsive Disorder
- Treatment-Resistant Depression
- Epilepsy
- Traumatic Brain Injury and Stroke
- Transcranial Magnetic Stimulation (TMS)
- Alzheimer's
- Treatment Resistant Depression
- Migraine
- Spinal Cord Stimulation (SCS)
- Chronic and Neuropathic Pain
- Spinal Cord Injury
- Vagus Nerve Stimulation (VNS)
- Epilepsy
- Treatment-Resistant Depression
- Obesity
- Peripheral Stimulation
- Assisted Breathing
- Epilepsy
- Fecal Incontinence
- Foot Drop
- Hypertension
- Migraine
- Neuropathic Pain
- Restless Legs Syndrome
- Sleep Apnea
- Stroke
- Urinary Conditions
- Gastric Modulation and Obesity
- Neurosurgical devices
- Radiosurgical Devices
- Neurosurgical Navigation and Equipment
- Image Guided Navigation (IGN)
- Intraoperative Magnetic Resonance Imaging (iMRI)
- Automated Surgical Systems
- Brain Monitoring
- Temperature Control Systems
- Neurovascular Intervention
- Ischemic Stroke
- Catheters, Stents and Perfusion devices
- Retrieval and Protection devices
- Ultrasound Thrombolysis
- Hemorrhagic Stroke
- Coils
- Liquid Embolics
- Stents
- Neurosoftware
- Attention Deficit Disorder
- Cognition and Aging
- Stress and Emotional Wellbeing
- Autism
- Addiction and Obesity
- Pain
- Schizophrenia
- 6: Neurodiagnostics Sector
- Neurodiagnostic Sector Overview
- FDA Approval and Reimbursement of Diagnostics
- Neuroimaging Technologies
- Computed Tomography (CT)
- Magnetic Resonance Imaging (MRI)
- Nuclear Medicine Imaging (PET, SPECT)
- Electro-encephalography (EEG)
- Magneto-encephalography (MEG)
- In Vitro Diagnostics
- In Vitro Diagnostics Regulatory Landscape
- Emerging Diagnostics for Alzheimer’s Disease
- Emerging Diagnostics for TBI
- Genetic Testing and Pharmacogenomics
- Protein Biomarker Assays
- Pattern Recognition in Diagnostics
- Emerging Diagnostics for Psychiatry
- Emerging Diagnostics for Autism
- Neuroinformatics
- Diagnostic Software
- 7: Private Neurotechnology Investment
- Private Investment in Neurotechnology
- Venture Capital Investment Trends
- Neurotech Venture Capital Investment
- Investing in Neuropharmaceuticals
- Investing in Stem Cells and Neuroregeneration
- Investing in Neurodevices
- Investing in Neurodiagnostics
- Private Company Financings, 2011
- Top financings 2004-2011
- Leading Neurotech Investors
- Leading Venture Capital Firms
- 8: Public Neurotechnology Investment
- Investing in Public Neurotech Companies
- Neurotech Stock Universe
- Neurotech Initial Public Offerings
- NASDAQ NeuroInsights Neurotech Index
- 9: Neurotechnology Research Centers
- Leading Neurotechnology Research Centers
- University of California, San Francisco (UCSF)
- University of California, Los Angeles (UCLA)
- University of California, San Diego (UCSD)
- Harvard
- Stanford University
- Massachusetts Institute of Technology (MIT)
- Columbia University
- Washington University, St. Louis
- University College London (UCL)
- Karolinska Institutet, Stockholm
- RIKEN Brain Science Institute, Japan
- Places to Watch
- National Brain Research Centre (NBRC), India
- Neurosciences Victoria, Australia (NSV)
- Univeristy of Helsinki, Finland
- 10: Leading Neurotechnology Regions
- The Global Neurotech Economy
- Nexus Ranking and Methodology
- Established Neurotech Nexus’
- Emerging Neurotech Nexus’
- Nascent Neurotech Nexus’
- Conclusions and Policy Recommendations
- 11: Company Profiles
- Neuropharmaceutical & Cell Therapy Companies: Private
- Neuropharmaceutical & Cell Therapy Companies: Public
- Neurodevice Companies: Private
- Neurodevice Companies: Public
- Neurodiagnostic Companies: Private
- Neurodiagnostic Companies: Public
- 12: Index
Abstract
Now in its eighth year, The Neurotechnology Industry 2012 Report is an expanded and updated 580 page report of brain and nervous system markets and treatments. It is the only publication to provide a comprehensive pipeline and market analysis to help investors, companies and entrepreneurs easily identify opportunities, understand the competitive landscape, determine risks and understand the dynamics of rapidly changing CNS markets.
The report includes detailed information on products in development globally for over 18 indications at 800 companies including Alzheimer's, addiction, ALS, anxiety, depressive disorders, epilepsy, migraine, mild cognitive impairment, Huntington's, multiple sclerosis, obesity, pain, Parkinson's, schizophrenia, age-related macular degeneration, sensory disorders, sleep disorders, traumatic brain injury and stroke.
Report Highlights
The Neurotechnology Industry 2012 Report provides a unified market-based framework to help executives, investors, and governments easily identify opportunities, understand the competitive landscape and visualize the dynamics of these rapidly growing markets.
- More than 500 profiles of public and private neurotech companies including drugs, devices and diagnostics
- Pipelines and market analysis for 18 brain and nervous system illnesses including: addiction, Alzheimer's disease, anxiety, attention disorders, depression, epilepsy, hearing loss, insomnia, mild cognitive impairment, migraine, multiple sclerosis, obesity, pain, Parkinson's disease, retinal disorders, schizophrenia, stroke, and traumatic brain injury
- Top neurotech investors, venture capital firms, and venture capital trends (1999-Q12012)
- Neurotech IPOs (2004-Q12012), M&A (2004-Q12012), Partnering and Licensing deals (2005-Q12012) and public neurotech stock performance
- Analysis of biological basis, current treatment options, and emerging therapeutic strategies
- Analysis of compounds, cell therapies and devices in clinical trials (and abandoned) by company, mechanism of action and stage of development for each indication
- Global and US market size, worldwide revenues for each indication
- Extensive discussion of specific technological, demographic, regulatory and intellectual property trends
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
